Ruconest not checked

IMMUNOe Research Centers · C1-esterase inhibitor

FollowEvery change as it happens, and a Monday email
Next date
Phase 4 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), COVID - 19
Main trialPhase 4
“Assessment of RUCONEST (C1 Esterase Inhibitor \[Recombinant\]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens”In the company’s words, NCT07932002 on ClinicalTrials.gov
Other names
C1-esterase inhibitor

Other drugs for COVID - 19

All 43 drugs for COVID - 19

Coming up1

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 31 Jul 2027 Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
Phase 4Completed 1 Dec 2019 A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Phase 2Completed 30 Mar 2024 Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Ruconest

Following is part of Solo: you see every change to Ruconest the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in